MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
PerkinElmer Operating Cash Flow 2011-2025 | PKI
Annual Operating Cash Flow PerkinElmer
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 628 M | 91.3 M | 1.41 B | 892 M | - | 363 M | 311 M | 288 M | 287 M | - | 282 M | 159 M | 152 M | 164 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.41 B | 91.3 M | 419 M |
Quarterly Operating Cash Flow PerkinElmer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 128 M | - | - | - | 148 M | - | - | - | 63.5 M | - | 541 M | 381 M | 283 M | - | 1.08 B | 761 M | 474 M | - | 410 M | 199 M | 60 M | - | 148 M | 41.5 M | -5.32 M | - | 152 M | 58.4 M | -14.6 M | - | 160 M | 102 M | 53.7 M | - | 202 M | 128 M | 32 M | - | 162 M | 101 M | 37.7 M | - | 185 M | 122 M | 67.7 M | - | 86.9 M | 38.8 M | 10.9 M | - | 113 M | 91.9 M | 15.5 M | - | 142 M | 94.6 M | 42.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.08 B | -14.6 M | 177 M |
Operating Cash Flow of other stocks in the Diagnostics research industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-21.7 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
65.4 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-48.7 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
884 K | $ 19.0 | -1.91 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-478 M | $ 20.75 | -2.01 % | $ 223 M |  China |
 |
Co-Diagnostics
CODX
|
-22.1 M | $ 0.23 | -3.91 % | $ 6.75 M | USA |
 |
Biocept
BIOC
|
-13.3 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-12.7 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
64.9 M | $ 39.22 | -0.44 % | $ 1.09 B | USA |
 |
Danaher Corporation
DHR
|
6.69 B | $ 230.27 | -0.02 % | $ 168 B | USA |
 |
DarioHealth Corp.
DRIO
|
-30.4 M | $ 10.22 | 1.79 % | $ 290 M | Israel |
 |
BioNano Genomics
BNGO
|
-68.9 M | $ 1.52 | -0.16 % | $ 1.93 M | USA |
 |
Exact Sciences Corporation
EXAS
|
211 M | $ 101.55 | -0.02 % | $ 18.8 B | USA |
 |
DexCom
DXCM
|
748 M | $ 68.16 | 0.87 % | $ 26.3 B | USA |
 |
Enzo Biochem
ENZ
|
-26.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
21.1 M | $ 26.59 | -0.47 % | $ 804 M | USA |
 |
Global Cord Blood Corporation
CO
|
614 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
-5.66 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-524 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-77 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-18.4 M | $ 19.3 | -0.92 % | $ 1.04 B | USA |
 |
Celcuity
CELC
|
-83.5 M | $ 100.62 | -1.59 % | $ 3.97 B | USA |
 |
Heska Corporation
HSKA
|
-21.8 M | - | - | $ 1.31 B | USA |
 |
Anixa Biosciences
ANIX
|
-7.34 M | $ 3.17 | -1.09 % | $ 101 K | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-18.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
2.72 B | $ 226.44 | -0.21 % | $ 41.1 B | USA |
 |
Guardant Health
GH
|
-240 M | $ 102.14 | -0.82 % | $ 12.5 B | USA |
 |
Myriad Genetics
MYGN
|
-8.7 M | $ 6.4 | -1.31 % | $ 580 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-7.4 M | $ 4.66 | -8.27 % | $ 2.5 M | USA |
 |
Neogen Corporation
NEOG
|
58.2 M | $ 7.27 | 1.89 % | $ 1.58 B | USA |
 |
Aspira Women's Health
AWH
|
-32.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
National Research Corporation
NRC
|
38.1 M | $ 18.6 | -0.35 % | $ 456 M | USA |
 |
Personalis
PSNL
|
-45.2 M | $ 8.14 | - | $ 482 M | USA |
 |
QIAGEN N.V.
QGEN
|
674 M | $ 45.94 | 1.26 % | $ 10.2 B |  Niderland |
 |
Illumina
ILMN
|
837 M | $ 134.51 | -0.33 % | $ 21.4 B | USA |
 |
Charles River Laboratories International
CRL
|
735 M | $ 202.78 | -0.43 % | $ 10.4 B | USA |
 |
RadNet
RDNT
|
233 M | $ 72.71 | -0.6 % | $ 5.31 B | USA |
 |
Soleno Therapeutics
SLNO
|
-69.1 M | $ 47.59 | -0.13 % | $ 1.91 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.33 B | $ 175.65 | -0.16 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
-48.6 M | $ 6.62 | -2.86 % | $ 858 M | USA |
 |
Motus GI Holdings
MOTS
|
-11.2 M | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
1.59 B | $ 253.7 | -0.07 % | $ 21.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.29 B | $ 181.2 | -0.9 % | $ 14.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
929 M | $ 687.59 | -0.13 % | $ 56.7 B | USA |
 |
Lantheus Holdings
LNTH
|
545 M | $ 67.17 | 0.69 % | $ 4.65 B | USA |